Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Cidara Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Cidara Therapeutics Divests Rezafungin to Focus on Advancing Cloudbreak DFC Pipeline
Details : Through the divestment, Mundipharma received the rights for Rezzayo (rezafungin acetate), an echinocandin antifungal, approved for the treatment of invasive candidiasis in adults.
Brand Name : Rezzayo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 24, 2024
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Cidara Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Mundipharma, Vectura Plan to Reformulate flutiform® to Reduce Carbon Footprint
Details : Two companies have a collaboration agreement to develop an environmentally friendly propellant for flutiform® (fluticasone propionate/formoterol fumarate) in a pMDI formulation.
Brand Name : Flutiform
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Cidara Therapeutics
Deal Size : $568.0 million
Deal Type : Partnership
Cidara Receives $11.14M Milestone Payment After European Approval of REZZAYO
Details : The payment triggered under the agreement is following the European approval of Rezzayo (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for invasive candidiasis in adults.
Brand Name : Rezzayo
Molecule Type : Peptide
Upfront Cash : $39.0 million
February 12, 2024
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Cidara Therapeutics
Deal Size : $568.0 million
Deal Type : Partnership
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rezzayo (rezafungin) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
Brand Name : Rezzayo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 22, 2023
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Cidara Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia.
Brand Name : Rezzayo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2023
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Cidara Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CD101 (rezafungin) is a novel, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections,demonstrated non-inferiority to the current standard of care in the treatment of candidemia and/or invasive candidi...
Brand Name : CD101
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 16, 2022
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Cidara Therapeutics
Deal Size : $568.0 million
Deal Type : Licensing Agreement
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
Details : Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Brand Name : CD101
Molecule Type : Peptide
Upfront Cash : $30.0 million
October 04, 2022
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Cidara Therapeutics
Deal Size : $568.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : European Medicines Agency filing is supported by the pivotal ReSTORE Phase III clinical trial results, where rezafungin (echinocandin/CD101) demonstrated non-inferiority to the current standard of care, caspofungin in the treatment of candidemia and/or i...
Brand Name : CD101
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 22, 2022
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Cidara Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results from ReSTORE showed primary endpoints were met with, 23.7% all-cause mortality on day 30 for rezafungin compared to 21.3% for caspofungin global cure on day 14 of 59.1% for rezafungin and 60.6% for caspofungin.
Brand Name : CD101
Molecule Type : Peptide
Upfront Cash : Not Applicable
April 25, 2022
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Cidara Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Cidara Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Result, did not demonstrate highly potent antifungal properties of CD101 against Candida in preclinical animal models of VVC, CD101 IV has enhanced potency and is only once-weekly therapy intended for treatment and prevention of life-threatening invasive...
Brand Name : CD101
Molecule Type : Peptide
Upfront Cash : Not Applicable
April 14, 2022
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Cidara Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?